RANDOM NEWS FROM ASCO

1.  For first line Metastatic Pancreatic Cancer:
        3 options Tarceva + Gemzar
                      FOLFIRINOX
and the new Abraxane-Gemzar
---------------------------------------------------and the winner is FOLFORINOX according to Michigan Researcher DR Philip Philip.
BUT ABRAXANE-GEMZAR is with less side effects and could be better tolerated by elderly patients

2.The point made by researcher that Treating early Breast cancer with adjuvant chemotherapy should be justified by Oncotype DX  (MammaPrint and now EndoPredict score, Breast Cancer Index (BCI))  findings is appreciated because about 0.5 % of women exposed to Chemotherapy  may develop Leukemia.  The risk was confirmed in a retrospective study reviewing data from the NCCN data base for 10 years.

3. Daratumumab, a monoclonal antibody used in myeloma showed a 47% mostly partial response and stable diseases.  But this is to follow very closely as it add a modality of treatment to be considered in refractory ahere nd late stage of disease, particularly in patient who had undergone most of the standard treatments. Keep an eye on this one, it may be a life savior in patients who have exhausted many options!

4.Predicting Oral Mucositis by Saliva source DNA could help us predict who will benefit from Palifermin (kepivance).  This remind me that Taxotere and Selumetinib gave much Mucositis, Just wonder if the nature of the drugs used is more important but who really knows how much predisposition plays into this!  will wait to hear more about this.

5 An eye catcher, BLINATUMOMAB, an anti-CD-19 bispecific T-cell engager (BiTE) could have a role in a disease where there is limited competition, Refractory ALL.  follow this one too...

6.  In triple negative Breast cancer, adding Bevacizumab did not make much difference.  I still wonder if our focus is wrong, it is not the anti-VEGF but the  anti-MEK that we need to use more to achieve.  OK LET'S TRY COMPARE THESE APPROACHES IN A CLINICAL TRIAL!  YES WHEN YOU THINK ABOUT IT, AN ANTI-MEK PRECEEDS THE ANTI-VEGF THING AND WILL HAVE HAVE OTHER IMPLICATIONS ON ADDITIONAL SIGNAL TRANSDUCTION PATHWAYS!

7.